ArticleBrain sciences2021
Predictors of Pharmaco-Resistance in Patients with Post-Stroke Epilepsy.
Article in Brain sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Antiepileptogenesis after stroke-trials and tribulations: Methodological challenges and recruitment results of a Phase II study with eslicarbazepine acetate.Epilepsia open · 2023Trial
- Prolonged focal impaired consciousness seizures: a biomarker of drug resistance in patients with epilepsy.Brain communications · 2026Article
- [Epilepsy in Patients With Moyamoya Angiopathy].Revista de neurologia · 2025Article
- Causal relations between ischemic stroke and epilepsy: A bidirectional Mendelian randomization study.Heliyon · 2024Article
- Observational
- Individualized Prediction of Drug Resistance in People with Post-Stroke Epilepsy: A Retrospective Study.Journal of clinical medicine · 2023Article
- Epilepsy in Cerebrovascular Diseases: A Narrative Review.Current neuropharmacology · 2023Review
- Impact of intensive rehabilitation on long-term prognosis after stroke: A Korean nationwide retrospective cohort study.Medicine · 2022Article
- Neutrophil-to-Lymphocyte Ratio Predicts Early Neurological Deterioration after Endovascular Treatment in Patients with Ischemic Stroke.Life (Basel, Switzerland) · 2022Article
- Latency of poststroke epilepsy can predict drug resistance.European journal of neurology · 2022Article
- Impact of Cardiovascular Diseases on Ischemic Stroke Outcomes.Journal of integrative neuroscience · 2022Review
- Poststroke Seizure and Epilepsy: A Review of Incidence, Risk Factors, Diagnosis, Pathophysiology, and Pharmacological Therapies.Oxidative medicine and cellular longevity · 2022Review
- Interictal epileptiform discharges as a predictive biomarker for recurrence of poststroke epilepsy.Brain communications · 2022Article
- Clinical Characteristics and Gene Mutation Analysis of Poststroke Epilepsy.Contrast media & molecular imaging · 2022Article
- Antiseizure medications for post-stroke epilepsy: A real-world prospective cohort study.Brain and behavior · 2021Article
- Blood pressure trajectories after stroke: Do they matter?Journal of clinical hypertension (Greenwich, Conn.) · 2021Article
- Systemic Inflammatory Response Index and Futile Recanalization in Patients with Ischemic Stroke Undergoing Endovascular Treatment.Brain sciences · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe study aimed to explore the clinical predictors of pharmaco-resistance in patients with post-stroke epilepsy (PSE).
methodsPatients with epilepsy secondary to cerebral infarct or spontaneous intracerebral hemorrhage were included. The study outcome was the occurrence of pharmaco-resistance defined as the failure of adequate trials of two tolerated and appropriately chosen and used antiseizure medication schedules, whether as monotherapies or in combination, to achieve sustained seizure freedom.
resultsOne-hundred and fifty-nine patients with PSE and a median follow-up of 5 (3-9) years were included. The mean age of the patients at stroke onset was 56.7 (14.9) years, and 104 (65.4%) were males. In the study cohort, 29 participants were pharmaco-resistant. Age at stroke onset [odds ratio (OR) 0.97, 95% confidence interval (CI) 0.93-0.99;
conclusionsPharmaco-resistance developed in approximately 20% of patients with PSE and was associated with younger age at stroke onset, stroke type and severity, status epilepticus occurrence, and seizure types.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.